Open House Biologics Discount Agreements 2025-01 Tender
Notice for Open House Biologics Discount Agreements 2025-01 - Infliximab in Germany. The reference ID of the tender is 139816382 and it is closing on 31 May 2026.
Tender Details
- Country: Germany
- Summary: Open House Biologics Discount Agreements 2025-01 - Infliximab
- DET Ref No: 139816382
- Deadline: 31 May 2026
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 267507-2026
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Infliximab (dosage form for subcutaneous injection) Infliximab (dosage form for intravenous use) The health insurance companies involved pursue the goal of entering into discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V The active ingredient infliximab (see below for the division into two lots). The contract is concluded as part of the open house biologics procedure of the participating health insurance companies: individual negotiations about the contents of the contract are not conducted; uniform conditions. The health insurance companies involved do not guarantee individual contractual partners any exclusivity. The contract term is a maximum of 24 months starting on April 1, 2025. The contract ends on March 31, 2027 at the latest, regardless of the date Conclusion of contract. Joining this open house biologics process is possible at any time within the contract period. Due to the existence of industrial property rights with regard to the contractual active ingredient or the In the case of the active ingredient combination in question, the participation and contract documents for lot 1 (infliximab (dosage form for subcutaneous injection)) are only made available to those pharmaceutical companies that supply the medicines offer/place the active ingredient or combination of active ingredients that is the subject of the proceedings on the market or make it credible to the TK, offer/invert such medicinal products within the contract term...
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINOpen House Biologics Discount Agreements 2025-01 - Infliximab - Germany Tender
The TECHNICIANS' HEALTH INSURANCE, a Government sector organization in Germany, has announced a new tender for Open House Biologics Discount Agreements 2025-01 - Infliximab. This tender is published on GermanyTenders under DET Ref No: 139816382 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-05-31.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
Fresh and verified Tenders from Germany. Find, search and filter Tenders/Call for bids/RFIs/RFPs/RFQs/Auctions published by the government, public sector undertakings (PSUs) and private entities.
- 1,000+ Tenders
- Verified Tenders Only
- New Tenders Every Day
- Tenders Result Data
- Archive & Historical Tenders Access
- Consultants for RFI/RFP/RFQ
- Tender Notifications & Alerts
- Search, Sort, and Filter Tenders
- Bidding Assistance & Consulting
- Customer Support
- Publish your Tenders
- Export data to Excel
- API for Tender Data
- Tender Documents
Fill out the form below and you will receive a call from us within 24 hours.
Get FREE SAMPLE TENDERS from Germany in your email inbox.
Copyright © 2014-2026 GermanyTenders.com. All Rights Reserved.